RG7212 anti-TWEAK mAb inhibits tumor growth through inhibition of tumor cell proliferation and survival signaling and by enhancing the host antitumor immune response.

@article{Yin2013RG7212AM,
  title={RG7212 anti-TWEAK mAb inhibits tumor growth through inhibition of tumor cell proliferation and survival signaling and by enhancing the host antitumor immune response.},
  author={Xuefeng Yin and Leopoldo L. Luistro and Hua Zhong and Melissa Smith and Tom Nevins and Kathleen J Schostack and Holly Hilton and Tai-An Lin and Theresa Truitt and Denise Biondi and Xiaoqian Wang and Kathryn Packman and Jim Rosinski and Windy Berkofsky-Fessler and Jian-Ping Tang and Saumya Pant and David Geho and Suzana M Vega-Harring and Mark Demario and Hy Levitsky and Mary Simcox},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2013},
  volume={19 20},
  pages={5686-98}
}
PURPOSE To explore the role of TWEAK in tumor growth and antitumor immune response and the activity and mechanism of RG7212, an antagonistic anti-TWEAK antibody, in tumor models. EXPERIMENTAL DESIGN TWEAK-induced signaling and gene expression were explored in tumor cell lines and inhibition of these effects and antitumor efficacy with RG7212 treatment was assessed in human tumor xenograft-, patient-derived xenograft, and syngeneic tumor models and phase I patients. Genetic features correlated… CONTINUE READING
Highly Cited
This paper has 912 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

A phase I monotherapy study of RG7212, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancers.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2015
View 6 Excerpts

912 Citations

0200400600'14'16'18
Citations per Year
Semantic Scholar estimates that this publication has 912 citations based on the available data.

See our FAQ for additional information.

References

Publications referenced by this paper.
Showing 1-10 of 48 references

A first-in-human phase I monotherapy study of RG7212, a novel monoclonal antibody targeting TWEAK signaling in patients with advanced solid tumors

U Lassen, D Meulendijks, +3 authors JHM Schellens
Eur J Cancer 2012;48:12 • 2012
View 4 Excerpts
Highly Influenced

Signaling in innate immunity and inflammation.

Cold Spring Harbor perspectives in biology • 2012
View 10 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…